Article

Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small-cell lung cancer: protocol of IRICO study

2023-01-30

Abstract excerpt

<h4>Introduction: </h4> Combined treatment using anti-programmed death-ligand 1 antibody (anti-PD-L1) and platinum-etoposide is the current standard first-line treatment for patients with extensive-stage (ES) small cell lung cancer (SCLC). However, the best treatment for relapsed ES-SCLC after the first-line treatment remains unclear. There are some approved chemotherapeutic agents that can be used against ES-SCLC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 17587393-7b68-56fc-8029-0bea763bcf62
DOI: 10.21203/rs.3.rs-2372547/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small-cell lung cancer: protocol of IRICO studyDOI 10.21203/rs.3.rs-2372547/v1Read

Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity Read

Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity Read

A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancerSemantic proximity Read

[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity Read

Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity Read

Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity Read

Etoposide–Platinum Rechallenge in Small Cell Lung Cancer Worth More Application: A Multicenter Study and Web-Based Predictive ModelSemantic proximity Read

Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity Read

Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804).Semantic proximity Read

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.Semantic proximity Read

Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancerSemantic proximity Read

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read